Loading clinical trials...

A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension

A Multicenter, Randomized, Double-blind, Parallel, Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension

NCT04959305•Hanmi Pharmaceutical Company Limited

View on ClinicalTrials.gov

Summary

A multicenter, randomized, double-blind, parallel, phase 2 study to explore the dose of HCP1803 in patients with essential hypertension

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients with essential hypertension whose blood pressure measured in visit1 corresponds to the following conditions
•* mean sitSBP \<180 mmHg and mean sitDBP \< 110 mmHg for patients receiving any BP-lowering drug within 1 month prior to Visit 1
•* 140 mmHg ≤ mean sitSBP \< 180 mmHg and mean sitDBP \< 110 mmHg for patients not receiving BP-lowering drugs within 1 month prior to Visit 1
•2. Patients with essential hypertension who meet 140 mmHg ≤ mean sitSBP \< 180 mmHg and mean sitDBP \< 110 mmHg at Visit 2

Exclusion Criteria

•1. Difference between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean sitDBP at Visit 1
•2. Orthostatic hypotension with symptoms within 3 months prior to visit 1.
•3. Secondary hypertensive patient or suspected to be
•4. Uncontrolled diabetes mellitus(HbA1c \> 9%) or type I diabetes mellitus
•5. Active gout or hyperuricemia (uric acid ≥ 9mg/dL)
•6. Severe heart disease or severe neurovascular disease
•7. Moderate or malignant retinopathy
•8. Clinically significant hematological finding
•9. Severe renal diseases (eGFR\<30mL/min/1.73m2)
•10. Severe or active hepatopathy (AST or ALT ≥ 3 times of normal range)
+8 more criteria

Locations (1)

Donggguk University Ilsan Hospital

Goyang-si, Gyeonggi-do, South Korea

Key Dates

Start Date

April 22, 2021

Primary Completion Date

February 28, 2022

Completion Date

February 28, 2022

Last Updated

July 14, 2022

Enrollment

245

ACTUAL participants

Conditions

Hypertension

Interventions

HCP1803-3

DRUG

RLD2003

DRUG

RLD2004

DRUG

RLD2005

DRUG

HPP2003-3

DRUG

HPP2005

DRUG

Natural History of Noncirrhotic Portal Hypertension

NCT02417740

Cystic FibrosisImmunologic Deficiency Syndrome+3 more

View study

RECRUITING

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

NCT07480265

Hypertension (HTN)Hyperhomocysteinemia+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 14, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension

Inclusion Criteria

Exclusion Criteria

Natural History of Noncirrhotic Portal Hypertension

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication

Penn Medicine Healthy Heart

Preliminary Human Trials of F230 Tablets